Navigation Links
Patient Safety Technologies Reports First Quarter 2011 Results
Date:5/23/2011

S, INC.Consolidated Balance SheetsMarch 31, 2011(unaudited)December 31, 2010AssetsCurrent assetsCash and cash equivalents$

6,089,395$

1,896,034Restricted cash223,630223,630Accounts receivable457,153772,381Inventory, net927,6771,110,832Prepaid expenses62,404104,628Total current assets7,760,2594,107,505Property and equipment, net930,474979,833Goodwill1,832,0271,832,027Patents, net2,707,8472,789,083Other assets43,98839,038Total assets$

13,274,595$

9,747,486Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$

618,252$

2,605,669Warrant derivative liability781,420991,682Deferred revenue869,1631,477,720Accrued liabilities864,679942,472Total current liabilities3,133,5146,017,543Stockholders' equity Total stockholders' equity10,141,0813,729,943Total liabilities and stockholders' equity $

13,274,595$

9,747,486PATIENT SAFETY TECHNOLOGIES, INC.Consolidated Statements of OperationsFor the Three months Ended March 31,2011 (unaudited)2010 (unaudited)Revenues$

1,970,656$

2,364,819Cost of revenue1,041,1011,088,887Gross profit929,5551,275,932Operating expenses:Research and development29,46233,331Sales and marketing659,036994,116General and administrative1,071,8961,651,861Total operating expenses1,760,3942,679,308Operating loss(830,839)(1,403,376)Other incomeInterest expense(4,192)(6,333)Gain on change in fair value of warrant derivative liability210,2621,718,738Other income—51,944Total other income206,0701,764,349Income (loss) before income taxes(624,769)360,973Income tax (provision) benefit(3,773)32,573Net income (loss)(628,542)393,546Preferred dividends(123,959)(19,163)Net income (loss) applicable to common shareholders$

(752,501)$

374,383Income (loss) per common shareBasic$

(0.03)$

0.02Diluted$

(0.03)$

0.01Weighted average common shares outstanding:Basic 24,200,78523,456,063Diluted24,200,78525,199,632
'/>"/>

SOURCE Patient Safety Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, 2014 ... ;  Sorrento), an oncology company developing new treatments ... a privately-held immuno-oncology company developing proprietary Neukoplast ® ... therapy, announced today that the companies have entered ... generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for the ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North American ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... progressing steadily, which has resulted in fueling the ... The main purpose of these dermatology devices is ...
(Date:12/19/2014)... Capnia, Inc. (NASDAQ: CAPN ... based on its proprietary Sensalyze™ Technology Platform for ... results for the third quarter and nine months ... completion of our initial public offering (IPO), we ... initiated CoSense® commercial launch," said Anish Bhatnagar, M.D., ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8
... 2011 Cumberland Pharmaceuticals Inc. (Nasdaq: ... care and gastroenterology markets, today announced fourth quarter and full ... For the three months ended December 31, 2010, net revenue ... corresponding period in 2009. This quarterly revenue growth was largely ...
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today ... immediately. "I am pleased to have someone of ... Mark Guinan, Senior Vice President and Chief Financial Officer of ... will contribute to the solid financial leadership of our company ...
Cached Medicine Technology:Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 9Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 10Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 11Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 12Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 13
(Date:12/19/2014)... (PRWEB) December 19, 2014 Diet Doc ... date, current approach to weight loss by ... understanding. The professionals at the company understand that remaining ... side effects of eliminating carbohydrates and sugars from the ... tempted to abandon their weight loss goals. , ...
(Date:12/19/2014)... The global magnetic resonance imaging (MRI) ... is saturated with numerous players developing innovative technologies. ... as non-invasive nature, MRI systems have seen continued ... healthcare market. Rapid advances in the field imaging ... have greatly expanded the potential of therapeutic applications. ...
(Date:12/19/2014)... 19, 2014 If you have ever ... breathing, you probably wished you had an arsenal of ... cystic fibrosis, and other breathing disorders. Currently, the only ... avoiding triggers, but other common treatments do exist. ... in San Antonio, TX, 34 asthma educators responded to ...
(Date:12/19/2014)... 19, 2014 This is a professional ... global Gliquidone industry with a focus on the Chinese ... status of the Gliquidone manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
(Date:12/19/2014)... 2014 (HealthDay News) -- A new study suggests a ... severe hot flashes and night sweats -- and higher ... flashes are common during menopause, affecting about 60 percent ... women after menopause, since they then face a higher ... suggest women who exhibit moderate or severe menopausal symptoms ...
Breaking Medicine News(10 mins):Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2
... new study has shown that vision correction patients will ... Lasek surgery. Both types of surgeries are equally safe ... cut flaps in the cornea and rectify the shape. ... surface of the cornea. This helps in doing away ...
... report has suggested that Thursday may not be a good day ... might end up waiting longer in the hospital.// ,The ... the trend for five years have blamed the procedures in the ... requirements, as it is thought to be. ,It was ...
... have been warned about a potential hepatitis risk for those ... ,Authorities suspect that those who consumed food from McDonald's ... of contracting Hepatitis A. The medical officer confirmed that a ... was suffering the highly infectious stage of the virus. It ...
... million U.S. dollars to take the anti-bird flu initiative forward, in ... for 2007 as// compared to the spending allocated in 2006. ... bird flu control, Bayu Krishnamurthi, the added spending on bird flu ... drive. So far there have been 74 human cases of bird ...
... by scientists, promises protection against all strains of flu virus. It ... influenza A virus, that is the cause of outbreaks of both ... vaccine is expected to bestow life long immunity. The only other ... every year. ,The injection is yet to be ...
... Highly developed nations like the U.S, with a fast paced lifestyle ... of saturated fat which can cause an// avalanche of diseases. ... eat more and put on more weight, proves a recent ... adults who live with children that those who live without children ...
Cached Medicine News:
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: